慢性淋巴细胞白血病的瑞克特转变:当前的治疗挑战和不断发展的疗法
Zi-Chi Lin1, Ming-Jen Chan2,3, Tang-Her Jaing3,4
1Division of Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan 333423, Taiwan.
International journal of molecular sciences
|September 13, 2025
概括
里希特转换 (RT) 是慢性淋巴细胞白血病 (CLL) 患者的一种侵袭性淋巴瘤并发症. 目前的治疗方法提供了有限的生存益处,需要对新型免疫疗法和向药物的研究.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 里希特转换 (RT) 影响2-10%的慢性淋巴细胞白血病 (CLL) 患者,进展为具有不良预后的侵袭性淋巴瘤.
- 关键的RT风险因素包括未变异的IGHV,TP53和NOTCH1突变,刻板的B细胞受体和复杂的细胞遗传学.
研究的目的:
- 本综述总结了里希特转换的生物学,临床预测因素和治疗结果.
- 它强调了当前治疗策略和新兴的治疗方法,用于这种高风险的CLL并发症.
主要方法:
- 该综述综合了关于里希特转换生物学和临床数据的现有文献.
- 它分析了传统化学免疫疗法,强化疗法,干细胞移植和新药的结果.
主要成果:
- 传统的化疗免疫疗法 (R-CHOP) 显示出低响应率 (20-30%) 和短生存期 (6-12个月).
- 强化疗法和新兴疗法,如BTK/BCL-2抑制剂,提供了适度的益处,而CAR T细胞疗法显示出更高的反应率,但复发频繁.
- 双特异性抗体在复发性/耐火性RT中表现出有希望的活性.
结论:
- 优化诱导,巩固和创新的免疫疗法对于改善里希特转换结果至关重要.
- 对这种独特的高风险淋巴瘤,对新的点和组合疗法的进一步研究至关重要.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K


![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)